Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299967 | 0.88 | PYCR1 (0.39) | SLC6A4HTR2AKCNH2GAAHPGD | |
| SCHEMBL4513196 | 0.85 | GAA (0.37) | GAAHPGDCCR5MEN1HTT | |
| SCHEMBL21713923 | 0.83 | GAA (0.36) | GAAHPGDCCR5MEN1HTT | |
| SCHEMBL23604474 | 0.83 | BACE1 (0.41) | BACE1 | |
| SCHEMBL4471859 | 0.81 | EDNRB (0.36) | GAAHPGDMEN1HTTKMT2A | |
| SCHEMBL10699444 | 0.81 | APLNR (0.40) | GAACCR5MEN1HTTKMT2A | |
| SCHEMBL1922648 | 0.81 | APLNR (0.35) | GAAHPGDCCR5MEN1HTT | |
| SCHEMBL15912526 | 0.81 | ALDH1A1 (0.40) | GAAHPGDMEN1HTTKMT2A | |
| SCHEMBL3365459 | 0.81 | GAA (0.35) | GAAHPGDCCR5MEN1HTT | |
| SCHEMBL18149538 | 0.81 | CYP3A4 (0.37) | SLC6A4HTR2AGAAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-3860990-B1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2022-09-14 | — | — | EP | disclosed |
| EP-3177287-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2021-10-21 | — | — | US | disclosed |
| EP-3860990-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | Inventiva (FR) | 2021-08-11 | — | — | EP | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| CN-101379033-A | Secondary amines | ACTELION PHARMACEUTICALS LTD (CH) | 2009-03-04 | — | — | CN | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-04 | — | — | US | disclosed |
| EP-1768978-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
| EP-1768978-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006005914-A1 | 2, 4, 6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078216-B2 | Bisaryl amides as NRF2 activators | NFE2L2, KEAP1, NQO1 | SLC6A4 4323/4885HTR2A 1788/4885KCNH2 4682/4885 |
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | SLC6A4 3761/4885HTR2A 3203/4885KCNH2 2369/4885 |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | REN, ACE, AGTR2 | SLC6A4 2410/4885HTR2A 2555/4885KCNH2 1032/4885 |
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | YAP1, TEAD2, YES1 | SLC6A4 4648/4885HTR2A 4577/4885KCNH2 4349/4885 |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | SLC6A4 4648/4885HTR2A 4577/4885KCNH2 4349/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | SLC6A4 2577/4885HTR2A 4397/4885KCNH2 1536/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | SLC6A4 3221/4885HTR2A 1741/4885KCNH2 4840/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | SLC6A4 504/4885HTR2A 860/4885KCNH2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.